EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management

Yoshitaka Saito

Current Treatment Options in Oncology · 2025

DOI: 10.1007/s11864-025-01302-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2025. Verfasst von Yoshitaka Saito. Beteiligte Einrichtung: Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Te…. Hauptthemen laut MEDLINE: Taxoids, Acute Pain, Bridged-Ring Compounds, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Taxane-associated acute pain syndrome (T-APS) is one of the most common adverse effects of taxane treatment and significantly reduces the quality of life and activities of daily living of patients. T-APS is recognized as myalgia and arthralgia, which generally appear 1-3 days after taxane administration and last for approximately 7 days, at a wide range of sites. Recently, T-APS has been suggested to be not only an acute symptom but also a chronic symptom associated with chemotherapy-induced peripheral neuropathy (CIPN). The reported incidence of T-APS varies among studies, possibly owing to differences in observation points, evaluation methods, taxane administration methods, concomitant medications, or patient factors. Several factors, such as high taxane dose, paclitaxel use, metastatic setting, breast cancer, younger age, and co-administration of pegfilgrastim, are associated with symptom development. Several findings regarding T-APS management, such as prophylaxis using corticosteroids, Shakuyaku-Kanzo-to, and non-steroidal anti-inflammatory drugs (NSAIDs), are present. Corticosteroids for several days after taxane administration dose-dependently prevents and attenuates T-APS although we should be cautious about its longer administration. Prophylactic administration of Shakuyaku-Kanzo-to, a herbal compound, may be useful, although prescriptions are only available in limited areas. Etoricoxib, a selective cyclooxygenase-2 inhibiting NSAID, also reduces the incidence and severity of T-APS. Additionally, its prophylactic administration decreases CIPN. In contrast, evidence of symptomatic medication is limited. Taxanes are key chemotherapeutic agents used in the treatment of several types of cancer; therefore, further assessment of mechanisms of action and treatment of T-APS is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TaxoidsAcute PainBridged-Ring CompoundsAntineoplastic AgentsNeoplasmsHumansDisease ManagementQuality of LifeTreatment OutcomePain Management

Stichwörter der Autor:innen

ArthralgiaChemotherapy-induced peripheral neuropathyManagementMyalgiaTaxane-associated acute pain syndrome

Substanzen

TaxoidstaxaneBridged-Ring CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Teine-Ku, Sapporo, 006-8585, Japan. saito-yo@hus.ac.jp.

Zitieren

APA

Saito, Y. (2025). Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-025-01302-y

Vancouver

Saito Y. Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management. Current Treatment Options in Oncology. 2025. doi:10.1007/s11864-025-01302-y

BibTeX
@article{Saito2025,
  author = {Saito, Yoshitaka},
  title = {Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management},
  journal = {Current Treatment Options in Oncology},
  year = {2025},
  doi = {10.1007/s11864-025-01302-y}
}
Kostenlos starten →